Tenet Healthcare is shifting from a hospital-heavy operator into a higher-quality outpatient platform, with USPI driving margin expansion and growth. Strong execution, buybacks, and improving leverage support a disciplined Buy view.
Tenet Healthcare (THC) fits a balanced, moderate-risk, medium-term investment profile because the company is no longer just a hospital operator. It is increasingly a higher-quality healthcare platform built around two engines: a still-profitable hospital base and a fast-scaling ambulatory surgery business through USPI. That mix matters. In 2025, Ambulatory Care generated $5.172B of revenue versus $3.865B in 2023, while Hospital Operations revenue moved the other way, from $6.026B in 2023 to $5.126B in 2025 on the segment data provided. The business is shifting toward outpatient care, where margins are stronger and capital intensity is often lower.
Execution has also been solid. THC has beaten EPS estimates in 7 straight reported quarters, including Q1 2026 adjusted EPS of $4.82 versus a $4.17 estimate. Q1 2026 adjusted EBITDA reached $1.162B on a 21.6% margin, and adjusted free cash flow was $978M. Management also repurchased 1.35M shares for $318M in Q1 2026, a sign that capital allocation remains aggressive while leverage has come down to 2.24x EBITDA as of March 31, 2026.
The core bull case is straightforward: THC is using hospital cash flow to fund ambulatory expansion, buy back stock, and improve operating efficiency, while USPI gives it direct exposure to the long-running migration of procedures into lower-cost outpatient settings. The main restraint is valuation upside versus execution risk. Analyst consensus target stands at $243.43, but the company also faces payer mix pressure, exchange enrollment declines, labor inflation, and a still-heavy debt load of $13.17B at year-end 2025. That leaves THC attractive, but not without a few sharp edges. The stock looks more like a disciplined Buy than a table-pounding one.
Tenet Healthcare (THC) is a diversified healthcare services company headquartered in Dallas, Texas. It operates in two segments: Hospital Operations and Services, and Ambulatory Care. The company had 77,000 employees in the corporate data provided, while the 2025 10-K describes nearly 100,000 employees across the broader network at December 31, 2025, including approximately 5,600 Global Business Center employees in the Philippines supporting enterprise functions.
At December 31, 2025, the Hospital Operations segment included 50 acute care and specialty hospitals, 132 outpatient facilities, physician practices, and Conifer Health Solutions. The Ambulatory Care segment is led by USPI, which held ownership interests in 533 ambulatory surgery centers and 26 surgical hospitals at year-end 2025. By March 31, 2026, management said USPI had interests in 541 ASCs and 26 surgical hospitals, showing continued expansion early in the year.
The scale is meaningful. THC reported trailing 12-month revenue of $21.45B, EBITDA of $4.63B, trailing EPS of $19.24, and a market cap of about $16.83B. Profitability is healthy for a healthcare facilities operator, with a 17.94% operating margin and 7.94% net margin on the core valuation data. Return on equity was 30.29%, though that figure is helped by a leveraged capital structure rather than a pristine balance sheet.
That management line captures the current identity of THC. This is not a pure hospital turnaround story anymore. It is a portfolio reshaping story, with ambulatory care taking a larger role in earnings quality, growth, and investor perception.
THC’s business mix has changed materially over the last three years. Segment data shows Ambulatory Care represented 39.1% of segment revenue in 2023, 44.5% in 2024, and 50.2% in 2025. Hospital Operations moved from 60.9% in 2023 to 49.8% in 2025. That is a major mix shift in a short period, and it matters because the ambulatory business carries structurally better margins.
In Q1 2026, USPI generated $484M of adjusted EBITDA with a 36.7% margin. Same-facility system-wide revenues rose 5.3%, net revenue per case increased 5.6%, and same-facility case volume dipped just 0.3% despite winter storms. That is a strong mix-and-pricing profile. The hospital segment generated $678M of adjusted EBITDA with a 16.7% margin. Same-hospital inpatient adjusted admissions rose 0.6%, but revenue per adjusted admission declined 1.5% due to reduced exchange volumes and the prior-year impact of a $40M favorable out-of-period supplemental Medicaid item.
The contrast is clear. Hospitals remain large and cash generative, but ambulatory is the cleaner growth engine. Management’s 2026 midpoint guidance reinforces that. USPI midpoint adjusted EBITDA guidance is $2.180B, implying 7.6% growth versus 2025 normalized performance. Hospital segment midpoint adjusted EBITDA guidance is $2.455B, implying 2.6% growth. In plain English, the hospital business still pays the bills, but USPI is where the multiple expansion case lives.
Conifer adds another layer. The 10-K says Conifer provided one or more business process services to approximately 600 Tenet and non-Tenet hospitals and other clients nationwide at December 31, 2025. Tenet and CommonSpirit facilities represented about 44% of those clients. In January 2026, THC completed a transaction with CommonSpirit that returned Conifer to full ownership effective January 1, 2026. That gives THC more direct control over a services asset tied to revenue cycle and value-based care.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
THC does not sell a single consumer product. Its flagship economic asset is USPI, especially its ambulatory surgery center network. If there is one operating franchise that best explains the investment case, it is the ASC platform and its push into higher-acuity outpatient procedures.
Management highlighted total joint replacements as a standout example. In Q1 2026, USPI same-facility ASC total joints growth was 10.3%, and the earnings call described double-digit same-store volume growth in total joint replacements. That matters because total joints are not low-value commodity procedures. They are a sign that more complex, higher-revenue work is moving into ambulatory settings where THC already has scale.
USPI is also expanding service lines beyond orthopedics. The investor presentation said THC had 87 service line additions year to date in 2026. Management also said USPI had more than 150 robotic surgery programs in ASCs that are general surgery based. That is a useful signal. It shows the company is not simply adding boxes on a map. It is deepening capability inside the network.
The platform is growing through both acquisition and de novo development. In Q1 2026, THC invested $125M to acquire 7 ASCs and opened 3 de novo centers. The investor presentation said 10 facilities were added in the quarter. For a business already operating more than 500 ASCs, that kind of steady expansion is not flashy, but it compounds. It is more like laying extra rail on an existing freight network than launching a new gadget. Slow, expensive, and very valuable if done well.
THC’s competitive advantage comes from scale, physician relationships, local density, and a business mix aligned with where healthcare delivery is moving. The strongest moat element is USPI’s size. The company describes USPI as the largest ambulatory platform in the country, and the disclosed footprint supports that claim as a serious competitive asset.
Scale helps in several ways. First, it improves physician recruitment and partnership appeal. Second, it supports purchasing leverage and operating standardization. Third, it creates a pipeline effect, where acquired centers can be upgraded from single-specialty to multispecialty operations. Management said USPI has a multiyear track record of acquiring assets, adding value clinically, bringing facilities in network, and reducing costs through supply chain and purchased services initiatives.
Technology is becoming a second layer of advantage. In the hospital segment, management described EMR-integrated tools such as ambient scribe, automated discharge summaries, and autonomous professional fee coding. It also said back-office AI automation has improved productivity and reduced third-party spend, and that Conifer analytics productivity has more than doubled. Those are not moonshot claims. They are workflow claims. In healthcare, workflow is where margins go to live or die.
The company’s governance approach also sounds more disciplined than the usual corporate AI sermon. Management said it uses a green-light or red-light process for pilots, scaling what works and shutting down what does not. That is refreshing. In a sector where buzzwords often arrive before savings, THC is at least talking like an operator.
Operational discipline is one of the better-supported parts of the THC story. Q1 2026 results were delivered despite two major winter storms, vendor cyber attack uncertainty, a 41% decline in respiratory admissions in hospitals, and exchange enrollment pressure. Yet consolidated adjusted EBITDA still reached $1.162B, about $50M above expectations according to the investor presentation.
Labor control stands out. Consolidated salary, wages, and benefits were 40.5% of net revenues in Q1 2026 versus 40.6% in Q1 2025. Holding that line while revenue mix was pressured is not trivial in healthcare. It suggests THC has become better at flexing staffing and throughput rather than simply absorbing volume shocks.
Throughput and length-of-stay management are central to the hospital strategy. Management said process automation, capacity controls, and engagement tools are improving recruitment, retention, and clinical throughput. In Q&A, the CEO tied shorter length of stay directly to the high-acuity strategy, arguing that better throughput creates capacity and avoids unnecessary capital spending on new beds.
Supply chain detail is more qualitative than numeric in the provided data, but management explicitly cited a broad-based supply chain and purchased services agenda at USPI that helps reduce costs and create efficiencies. The 10-K also notes concentration benefits in local markets, especially in Arizona and Texas outpatient centers, which can lower management, marketing, and resource utilization costs. That density can be a strength, though it also raises local-market concentration risk.
THC is positioned in a healthcare facilities market shaped by one dominant structural trend: procedures are moving out of the hospital and into outpatient settings. Industry context cited outpatient services as 54.31% of the U.S. hospital facilities market in 2025, with that segment projected to grow at 8.38% CAGR through 2031. McKinsey also noted that ambulatory surgery centers continue gaining share in procedures such as knee and hip arthroplasty.
That trend fits THC unusually well. USPI had interests in 541 ASCs and 26 surgical hospitals as of March 31, 2026, up from 461 ASCs at December 31, 2023. The company is not trying to invent the outpatient migration story. It is already standing in the middle of it with a very large net.
The hospital market remains large, but growth is slower and more exposed to reimbursement pressure, labor costs, and payer behavior. THC’s answer has been to push higher-acuity services in hospitals while shifting suitable procedures into ambulatory settings. That is a sensible two-lane strategy. Hospitals handle the complex work and preserve referral relevance; ASCs capture the lower-cost site-of-care shift and offer better margin economics.
The market opportunity is therefore less about raw healthcare spending growth and more about share capture inside the care setting mix. THC’s ambulatory revenue rose from $3.865B in 2023 to $5.172B in 2025. That is the kind of number that turns a secular theme into a company-specific earnings driver.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
THC serves several customer groups at once. Patients are the obvious end users, but economically the company also serves physicians, health systems, managed care payers, and enterprise clients through Conifer. That multi-sided model matters because a healthcare facility operator wins only when all of those parties keep showing up.
For patients, the value proposition differs by segment. Hospitals provide acute, specialty, trauma, transplant, cardiac, neurosciences, obstetrics, and emergency services. ASCs and surgical hospitals provide lower-cost, more convenient access for procedures in orthopedics, gastroenterology, pain management, ENT, ophthalmology, and urology. The 10-K says USPI facilities offer greater affordability, predictability, flexibility, and convenience for patients and physicians.
For physicians, THC’s pitch is operational support and volume opportunity. Management repeatedly emphasized creating the right operating environment for surgeons, improving OR design, and helping centers expand from single-specialty to multispecialty operations. That matters because physicians are not captive. The 10-K is blunt that most physicians can admit patients to competing facilities at any time.
For payers, THC offers network breadth and lower-cost sites of care through USPI. For Conifer clients, the company provides revenue cycle management, denials management, coding, patient access, and value-based care services. At December 31, 2025, Conifer served about 600 Tenet and non-Tenet hospitals and other clients nationwide. That gives THC a customer base beyond its owned facilities, which adds some diversification to the model.
THC’s main public-market peers are HCA Healthcare (HCA), Universal Health Services (UHS), and Community Health Systems (CYH). HCA is the giant in the room, with 186 hospitals and about 2,400 ambulatory sites across 20 states and the UK. UHS reported 2025 revenue of $17.4B with 29 acute care hospitals and 49 ambulatory locations. CYH remains a relevant hospital operator peer.
THC’s differentiation is its balance between hospitals and a very large ASC platform. HCA has broader scale overall, but THC has unusually strong direct exposure to ambulatory surgery through USPI. UHS has meaningful acute care and behavioral health exposure, but not the same ASC footprint. CYH is more hospital-centric and generally weaker in quality of mix.
Competition also comes from nonprofit systems, government-supported hospitals, physician-owned centers, private equity-backed ASC operators, freestanding emergency departments, urgent care centers, and imaging providers. The 10-K notes that some competitors benefit from tax-exempt financing, charitable support, tax advantages, or discounted drug pricing. In other words, healthcare competition is not always a clean commercial knife fight. Sometimes one side also gets a subsidy and a tax break.
THC’s defense is local relevance, physician alignment, managed care contracting breadth, and service-line depth. The 10-K says the top 10 managed care payers generated 69% of managed-care net patient service revenues in 2025. That concentration is a risk, but it also shows THC is large enough to matter in payer networks. Size does not guarantee pricing power, but irrelevance guarantees the opposite.
The most important macro issue for THC is not geopolitics in the usual sense. It is U.S. healthcare policy, payer behavior, labor inflation, and insurance coverage shifts. The 10-K says certain Affordable Care Act provisions, including enhanced premium tax credits, expired at the end of 2025, leading to significant premium increases and expected decreases in enrollment and insurance coverage beginning in 2026.
Management quantified the hit. The 2026 EBITDA bridge includes a $250M impact from expiration of enhanced premium tax credits, split as $30M in ambulatory and $220M in hospitals. In Q1 2026, same-store exchange admissions in hospitals were down about 10% versus Q1 2025, and exchange revenues represented about 6% of consolidated revenue, down 9% from the prior year. That is a real headwind, not a theoretical one.
Labor remains another macro pressure point. The 10-K describes shortages of physicians, advanced practice clinicians, and critical-care nurses in certain disciplines and geographies. It also notes California healthcare minimum wage increases effective in October 2024 with further annual increases through 2028. THC has managed this well so far, but healthcare labor rarely gets cheaper out of kindness.
On the positive side, the outpatient migration trend is a structural tailwind that can offset some reimbursement and labor pressure. Technology adoption is another tailwind if it improves throughput and documentation efficiency. THC’s Q1 2026 results suggest those offsets are already showing up in margins and cash flow.
Net debt has fallen to 2.24x EBITDA as of March 31, 2026, even after $318M of share repurchases in Q1, but the company still carried $13.17B of debt at year-end 2025.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 adjusted EPS of $4.82 beat the $4.17 estimate, extending a streak of 7 straight quarterly EPS beats alongside a 21.6% adjusted EBITDA margin.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →USPI’s 2026 midpoint adjusted EBITDA guidance of $2.180B implies 7.6% growth, while the hospital segment’s $2.455B midpoint points to a slower 2.6% increase.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →With analyst consensus at $243.43 and our fair value set at $225, the stock still offers upside, but the valuation leaves less room for error than the operating momentum suggests.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s price framework places THC at a $225 fair value, with stronger upside cases only emerging if execution pushes the stock toward the $250 and $280 scenarios.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →THC has become a more interesting company than its old reputation suggests. The hospital segment is steadier, the ambulatory business is larger and more profitable, Conifer adds a services layer, and capital allocation has been forceful. Q1 2026 showed that the company can still grow EBITDA and free cash flow even while managing storms, payer mix pressure, and exchange enrollment declines.
That said, this is not a risk-free compounder. Debt is still high in absolute terms, policy changes can hit coverage and reimbursement, and hospital operators never get to ignore labor. THC earns a Buy because the facts point to a business improving faster than the market is fully rewarding, not because the risks have disappeared.
For a medium-term investor, the key attraction is the combination of cash flow, mix shift, and valuation. If management keeps expanding USPI, protecting hospital margins, and using cash intelligently, THC has a credible path to grow into and beyond our fair value estimate of $225. In this market, that is enough. It does not need to be perfect. It just needs to keep executing.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Tenet Healthcare Corporation (THC) climbs after hours after posting strong Q2 2026 results and raising full-year guidance. The hospital and ambulatory care operator delivered higher EPS, stronger EBITDA, and improved margins, fueling a sharp move toward its 52-week high as investors react to the upbeat outlook.
The Kansas Fed manufacturing index came in well above expectations in July, signaling continued expansion in the Tenth District. But the details were less upbeat: hiring slowed sharply, new orders cooled and price pressures stayed elevated, reinforcing a cautious outlook for the Fed and the broader economy.
The Fed’s total assets rose to $6.747 trillion, reinforcing that runoff is still paused and liquidity remains abundant. Reserves climbed to about $3.1 trillion while ON RRP usage stayed near zero, signaling calm funding conditions even as inflation and labor data continue to drive rate expectations.